

D25

WO: D.

762.

XP-002101518

1/1 - (C) WPI / DERWENT
AN - 82-82639E 25!
AP - JP870021367 870218
PR - JP810021367 810218; JP870021367 870218
TI - Immuno-controlling agent - comprising trans-1-cinnamyl
4-di:phenyl:methyl:piperazine
IW - IMMUNO CONTROL AGENT COMPRISE TRANS CINNAMYL DI PHENYL
METHYL PIPERAZINE
PA - (EISA) EISAI CO LTD
PN - JP57136518 A 820823 DW8239 003pp
- JP1021813B B 890424 DW8920 000pp
ORD - 1982-08-23
IC - A61K31/49 ; C07D295/02
FS - CPI
DC - B03
AB - J57136518 Immuno-controlling agent comprises
trans-1-cinnamyl-4-diphenyl-methyl piperazine
(Cinnalazine) of formula (I). Cinnalazine has
vasospasmolytic action, cerebral vasodilator action,
blood flow-improving action, cerebral blood
current-increasing action. It is used to treat e.g.
vertigo, headache, numbness based on cerebral blood
flow dyserethesia caused by e.g. cerebral apoplexy
(encephalorrhgia, cerebral thrombus, cerebral embolus
etc.), arteriosclerosis, hypertensive cerebral
circulation insufficiency, caput injury sequella.
- Cinnalazine has both of immuno-increasing action and
immuno-inhibiting action and may thus be used for
treating diseases which may be cured by increasing or
inhibiting immunoreaction on living bodies, e.g.
cancer, bacterial infectious diseases, allergic
diseases, rheumatism and inflammation. When
administered as immuno-controlling agent, dosage is
usually 10-300 mg/adult/day orally or parenterally.